Betrixaban

• Description :

  Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban shows antithrombotic effect[1][3].

• Product Name Alternative :

  PRT054021

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H373

• Target :

  Factor Xa

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/Betrixaban.html

• Purity :

  98.02

• Solubility :

  DMSO : 25 mg/mL (ultrasonic)

• Smiles :

  N=C(N(C)C)C(C=C1)=CC=C1C(NC2=CC=C(OC)C=C2C(NC(C=C3)=NC=C3Cl)=O)=O

• Molecular Formula :

  C23H22ClN5O3

• Molecular Weight :

  451.91

• Precautions :

  H302, H373

• References & Citations :

  [1]Zhang P, et al. Discovery of Betrixaban (PRT054021), N- (5-chloropyridin-2-yl) -2- (4- (N, N-dimethylcarbamimidoyl) benzamido) -5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg Med Chem Lett. 2009 Apr 15;19 (8) :21|[2]Lu G, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013 Apr;19 (4) :446-51.|[3]Chan NC, et al. Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag. 2015 Jun 26;11:343-51.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [330942-05-7]